Immutrin, a Cambridge-based biotech co-founded by Nobel laureate Gregory Winter, has raised between $86 million and $87 million to advance its antibody drug candidate for amyloidosis. The therapy is designed to deplete protein deposits in patients with the condition, specifically targeting ATTR-CM, a genetic disorder affecting the heart.
The antibody treatment targets amyloidosis, a rare disease where misfolded proteins accumulate in organs and tissues. ATTR-CM refers to transthyretin amyloid cardiomyopathy, a progressive heart disease that can be fatal without treatment. Clinical trial details and efficacy data were not disclosed in the funding announcement.
The company has not announced specific regulatory timelines or when the therapy might enter clinical trials. Development of amyloidosis treatments typically requires multiple phases of clinical testing before potential regulatory approval.
Immutrin enters a competitive landscape for ATTR treatments, with established players including Pfizer, Alnylam Pharmaceuticals, and BridgeBio already developing or marketing competing therapies. The substantial funding round signals investor confidence in the company's differentiated approach to treating this rare disease.
The funding will enable Immutrin to advance its antibody candidate through preclinical development and potentially into human trials, offering hope for patients with limited treatment options for this progressive condition.